Adherence to oral hormonal anticancer agents in breast cancer

Tumori. 2023 Jun;109(3):262-268. doi: 10.1177/03008916221096183. Epub 2022 May 21.

Abstract

There is an increasing trend towards using oral antitumoral agents in oncological patients. Compared to parenteral therapy, oral treatment offers convenience for both the patient and the healthcare system, with similar efficacy. However, the benefit deriving from oral drugs will be obtained only if patients adhere strictly to the treatment. Medical oncologists must therefore seek to optimize patient adherence. Breast cancer patients, particularly, are often treated with oral hormonal anticancer agents. In this review, we summarized evidence about adherence of breast cancer patients to oral hormonal anticancer agents and the consequences of poor compliance, the barriers to oral treatment and strategies to overcome them.

Keywords: Adherence; adjuvant endocrine therapy; breast cancer; oral antitumoral agents.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Chemotherapy, Adjuvant
  • Female
  • Humans
  • Medication Adherence
  • Mouth Neoplasms*
  • Patient Compliance

Substances

  • Antineoplastic Agents, Hormonal
  • Antineoplastic Agents